# BEAM — local-model

## Metadata

ticker: BEAM
arm: local-model
judge_prompt_version: v2
context_sha256: bb6064218eb2ce2225f10ece927df1cbd6b02a721e217a0a10b5e555f3ce296a
local_model_served_name: financial-lora
local_model_dir: qwen-ft
local_model_backend: openai
local_model_url: http://vllm.financial-agent.svc:8000
local_model_sampling: {"max_tokens": 512, "min_p": 0.0, "repetition_penalty": 1.1, "temperature": 0.1, "top_k": 20, "top_p": 0.8}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 24.37,
  "currency": "USD",
  "market_cap": 2517120512.0,
  "forward_pe": -5.1398644,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin": -0.55449003,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] # Key Takeaways from the Latest SEC Filings

## Financial Position and Losses
The company has accumulated significant operating losses since inception, with a net loss of $80.0 million in 2025, $376.7 million in 2024, and $132.5 million in 2023. As of December 31, 2025, the accumulated deficit reached $1.6 billion. However, the company maintains $1.2 billion in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months.

## Capital Requirements and Funding Challenges
Substantial additional funding will be required to support ongoing research and development, clinical trials, and potential commercialization efforts. The company has no committed source of additional capital beyond its credit facility with Sixth Street Lending Partners. If unable to raise capital on acceptable terms, the company may be forced to delay, reduce, or eliminate research programs and commercialization efforts.

## Strategic Restructuring
In October 2023, the company announced a portfolio reprioritization and strategic restructuring that included cost-reduction initiatives, resulting in the pausing or elimination of certain pipeline programs.

## Development Stage and Risks
The company is early-stage, founded in January 2017, with operations beginning in July 2017. It has not completed any pivotal clinical trials or obtained marketing approvals for any product candidates. The company expects to continue incurring significant losses for the foreseeable future and may never achieve profitability.

## Dilution and Financing Risks
Future capital raises through equity or debt may dilute shareholder ownership and restrict operations. Financing through collaborations or licensing arrangements could require relinquishing valuable rights to technologies or product candidates.

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors, with the primary ones being:

## Financial Position and Capital Needs
- **Substantial accumulated losses**: The company has an accumulated deficit of $1.6 billion as of December 31, 2025, with net losses of $80.0 million, $376.7 million, and $132.5 million for 2025, 2024, and 2023, respectively.
- **Expectation of continued losses**: The company expects to incur losses for the foreseeable future and may never achieve profitability.
- **Need for additional funding**: Substantial additional capital will be required to continue operations, expand clinical trials, and pursue commercialization efforts. Without adequate funding, the company may be forced to delay, reduce, or eliminate research and development programs.

## Product Development and Commercialization Challenges
- **No completed pivotal trials**: The company has not completed any pivotal clinical trials and has no product candidates approved for commercialization.
- **Long development timeline**: Developing new medicines typically takes 10 to 15 years from discovery to patient availability.
- **Unproven capabilities**: The company has not yet demonstrated the ability to successfully complete pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale medicines, or conduct necessary sales and marketing activities.

## Limited Operating History
- **Early-stage company risks**: As a relatively new operating company in a rapidly evolving field, the company faces significant uncertainty in predicting future success and may encounter unforeseen expenses and complications.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc., a biotechnology company listed on the Nasdaq Global Select Market under the ticker symbol BEAM, reports its financial health through key metrics such as net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income, net loss, net cash provided by operating activities, net cash used in investing activities, net cash used in financing activities, total assets, total liabilities, shareholders' equity, net sales, gross profit, net income

### Recent Developments

Limited recent news is available for analysis at this time. However, Beam Therapeutics' most recent SEC filings (10-Q filed August 4, 2026, and 10-K filed February 24, 2026) emphasize significant risk factors that investors should monitor closely. The company continues to face financial headwinds, with a negative profit margin of -55.4% and net losses of $86.5 million, indicating the company remains in a pre-profitability stage typical of early-stage biotech firms. Investors should closely track clinical trial progress, regulatory developments, and cash burn rates, as these will be critical to the company's long-term viability and stock performance.

### SEC Filing Highlights

Beam Therapeutics reported a net loss of $80.0 million in 2025 with an accumulated deficit of $1.6 billion, though the company maintains $1.2 billion in cash expected to fund operations through at least the next 12 months. The company faces substantial capital requirements for ongoing R&D and clinical trials, with no committed funding sources beyond its credit facility with Sixth Street Lending Partners. A strategic restructuring initiated in October 2023 included cost-reduction initiatives and the pausing or elimination of certain pipeline programs. As an early-stage company founded in 2017 with no completed pivotal trials or marketing approvals, Beam expects to continue incurring significant losses and may never achieve profitability. Future funding through equity or debt raises risks shareholder dilution, while collaboration arrangements could require relinquishing valuable technology rights.

### Primary Risk Factors Disclosed

#### Financial Position and Capital Needs
- The company has an accumulated deficit of $1.6 billion as of December 31, 2025, with net losses of $80.0 million, $376.7 million, and $132.5 million for 2025, 2024, and 2023, respectively.
- The company expects to incur losses for the foreseeable future and may never achieve profitability.
- The company requires substantial additional capital to continue operations, expand clinical trials, and pursue commercialization efforts. Without adequate funding, the company may be forced to delay, reduce, or eliminate research and development programs.

#### Product Development and Commercialization Challenges
- The company has not completed any pivotal clinical trials and has no product candidates approved for commercialization.
- Developing new medicines typically takes 10 to 15 years from discovery to patient availability.
- The company has not yet demonstrated the ability to successfully complete pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale medicines, or conduct necessary sales and marketing activities.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. is an early-stage biotechnology company founded in 2017 and listed on the Nasdaq Global Select Market, focused on developing base editing medicines, with an accumulated deficit of $1.6 billion and $1.2 billion in cash on hand as of its most recent filings. The stock is notable now as a high-risk, high-optionality play on a novel gene-editing platform, set against a backdrop of ongoing net losses, a strategic restructuring that paused or eliminated certain pipeline programs, and no product candidates yet approved for commercialization. The single most important near-term variable shaping the investment outcome is clinical trial progress — specifically, whether Beam can generate meaningful efficacy and safety data sufficient to advance candidates toward pivotal trials and attract additional non-dilutive funding.

### Outlook
The directional outlook for Beam Therapeutics is **cautious**, reflecting the realities of a pre-revenue, pre-approval biotech operating with a substantial accumulated deficit and no committed funding sources beyond its existing credit facility. The primary tailwind is the company's $1.2 billion cash position, which provides a meaningful operational runway and reduces near-term liquidity risk, alongside the broader scientific promise of base editing as a differentiated approach within the gene-editing landscape. Headwinds are significant: persistent net losses, a negative profit margin, a history of pipeline restructuring, and the inherent 10-to-15-year development timeline for novel medicines all weigh on the risk-reward profile. Investors should monitor clinical trial readouts as the most consequential catalyst — positive efficacy and safety data would materially strengthen the thesis by validating the platform and improving the company's ability to attract partnership capital on favorable terms. Conversely, trial setbacks, accelerating cash burn, or the need to raise equity capital at dilutive terms would weaken the thesis. Regulatory signals from the FDA and the evolution of the broader competitive gene-editing environment are additional variables worth tracking closely. The view would shift toward more constructive if Beam demonstrates clear clinical proof-of-concept and secures a meaningful collaboration arrangement that reduces its dependence on capital markets.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "founded in 2017"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "founded in January 2017, with operations beginning in July 2017," confirming the founding year.

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: Both the RAG SEC Highlights and RAG Risk Factors explicitly state "accumulated deficit reached $1.6 billion as of December 31, 2025."

---

CLAIM: "$1.2 billion in cash on hand"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly state "the company maintains $1.2 billion in cash, cash equivalents, and marketable securities."

---

CLAIM: "no product candidates yet approved for commercialization"
LABEL: SUPPORTED
REASON: The RAG Risk Factors and SEC Highlights both state "no product candidates approved for commercialization" and "has not completed any pivotal clinical trials or obtained marketing approvals."

---

**OUTLOOK**

---

CLAIM: "no committed funding sources beyond its existing credit facility"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights state "no committed source of additional capital beyond its credit facility with Sixth Street Lending Partners."

---

CLAIM: "$1.2 billion cash position"
LABEL: SUPPORTED
REASON: Explicitly stated in the RAG SEC Highlights as "$1.2 billion in cash, cash equivalents, and marketable securities."

---

CLAIM: "a negative profit margin"
LABEL: SUPPORTED
REASON: The stock data shows profit_margin of -0.55449003 (approximately -55.4%), confirming a negative profit margin; the Recent Developments section also states "-55.4%."

---

CLAIM: "10-to-15-year development timeline for novel medicines"
LABEL: SUPPORTED
REASON: The RAG Risk Factors explicitly state "Developing new medicines typically takes 10 to 15 years from discovery to patient availability."

---

**Claims NOT present / forward-looking claims requiring additional checks:**

There are no explicit price targets, specific percentage thresholds, named product milestones with dates, specific ratio figures (e.g., P/E cited numerically), or other quantitative forward-looking numbers in the Outlook section beyond those already evaluated above. The references to "FDA," "partnership capital," "collaboration arrangement," "equity capital at dilutive terms," "trial setbacks," and "accelerating cash burn" are qualitative directional statements without specific quantitative claims attached, so they fall outside the scope of this audit's quantitative checks.

---

**SUMMARY TABLE**

| # | Claim | Label |
|---|-------|-------|
| 1 | Founded in 2017 | SUPPORTED |
| 2 | Accumulated deficit of $1.6 billion | SUPPORTED |
| 3 | $1.2 billion in cash on hand | SUPPORTED |
| 4 | No product candidates approved for commercialization | SUPPORTED |
| 5 | No committed funding sources beyond existing credit facility | SUPPORTED |
| 6 | $1.2 billion cash position (Outlook) | SUPPORTED |
| 7 | Negative profit margin | SUPPORTED |
| 8 | 10-to-15-year development timeline | SUPPORTED |

All quantitative and forward-looking claims in the Executive Summary and Outlook are **SUPPORTED** by the source data. No unsupported or inference-only claims were identified.
